Tags : Breakthrough approval


AstraZeneca’s Tezepelumab (thymic stromal lymphopoietin antagonist) Receives FDA BT Designation

Shots:  The designation is based on P-IIb PATHWAY assessing (tezepelumab vs PBO) in patients with asthma exacerbations, uncontrolled asthma receiving inhaled corticosteroids/LA- β2-agonists w/o oral corticosteroids and additional asthma controllers  P-IIb PATHWAY involves administering of (70/210mg q4w or 280mg q2w) which showed reduction in annual asthma exacerbation rate reductions of 62%, 71% and 66% vs […]Read More